GlaxoSmithKline

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Established: 1929-01-01

Employees: 70.2K

Market Cap: $90B

Website: http://www.gsk.com

Introduction: GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Clinical Trials

Post-marketing Safety Monitoring Program of Fluticasone Propionate (FP) in Chinese Subjects With Asthma Aged 1 to <4 Years

Completed

Conditions: Asthma

Interventions: Drug: Fluticasone propionate

First Posted Date: 2017-09-06

Last Posted Date: 2019-10-02

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 158

Registration Number: NCT03273946

Locations: 🇨🇳
GSK Investigational Site, Shanghai, China

Subject Insights to Understand the Hand Osteoarthritis (HOA)

Completed

Conditions: Osteoarthritis

Interventions: Other: Michigan Hand Outcomes Questionnaire
Other: Real-time data capture app

First Posted Date: 2017-09-05

Last Posted Date: 2018-10-16

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 30

Registration Number: NCT03271203

Locations: 🇬🇧
GSK Investigational Site, Bollington, Cheshire, United Kingdom

Impact of Rotavirus Vaccination on Hospital Pressures at a Large Paediatric Hospital in the UK: an Ecological Study

Completed

Conditions: Gastroenteritis

Interventions: Other: No intervention

First Posted Date: 2017-09-05

Last Posted Date: 2017-09-21

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 1

Registration Number: NCT03271593

A Study to Compare the Pharmacokinetics (PK) of GSK2982772 Following Administration of Different Modified Release (MR) Formulations in Capsule and MR Tablet Formulations Relative to an Immediate Release (IR) Tablet Formulation and to Check the PK of MR Formulation in Capsule Following Repeat Doses

Phase 1

Completed

Conditions: Autoimmune Diseases

Interventions: Drug: GSK2982772 Modified Release
Drug: GSK2982772 Immediate Release

First Posted Date: 2017-08-30

Last Posted Date: 2021-08-13

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 45

Registration Number: NCT03266172

Locations: 🇬🇧
GSK Investigational Site, Nottingham, United Kingdom

A Study to Investigate the Stain and Plaque Removal Capability of Two Experimental Potassium Nitrate Dentifrices

Phase 2

Completed

Conditions: Oral Hygiene

Interventions: Drug: 5% KNO3 / 0.2542% NaF dentifrice with 0.5% spherical silica
Drug: 5% KNO3 / 0.2542% NaF dentifrice with 1% spherical silica and 5% STP
Drug: 5% KNO3 / 0.2542% NaF dentifrice with 6% abrasive silica
Drug: 5% KNO3 / 0.2543% NaF dentifrice with 16% abrasive silica and 5% STP